0001000694
false
0001000694
2023-10-03
2023-10-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
October 3, 2023
NOVAVAX, INC.
(Exact name of registrant as specified
in charter)
| Delaware |
|
0-26770 |
|
22-2816046 |
|
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
700 Quince Orchard Road
Gaithersburg, Maryland 20878
(Address of Principal Executive Offices,
including Zip Code)
(240) 268-2000
(Registrant’s telephone number,
including area code)
(Former name or former address, if changed
since last report.)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| ¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
|
| ¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
|
| ¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
|
| ¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section
12(b) of the Act:
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which
registered |
| Common Stock, Par Value $0.01 per share |
|
NVAX |
|
The Nasdaq Global Select Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01.
Regulation FD Disclosure.
On October
3, 2023, Novavax, Inc. (the “Company”) issued a press release announcing that the Company’s Novavax COVID-19 Vaccine,
Adjuvanted (2023-2024 Formula) (“NVX-CoV2601”) has received Emergency Use Authorization from the U.S. Food and Drug Administration
for active immunization to prevent COVID-19 in individuals aged 12 and older. A copy of the press release is attached as Exhibit 99.1
to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference.
The information
in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed to be “filed” for purposes of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section and shall not be deemed
incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended,
or the Securities Exchange Act of 1934, as amended, except as shall be expressly set forth by specific reference in such filing.
Item 9.01.
Financial Statements and Exhibits.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
NOVAVAX, INC. |
| |
|
|
| |
|
|
| Date: October 3, 2023 |
By: |
/s/ John A. Herrmann III |
| |
Name: |
John A. Herrmann III |
| |
Title: |
Executive Vice President, Chief Legal Officer and Corporate Secretary |
Exhibit 99.1
| |
 |
| Press Release |
|
Novavax 2023-2024 COVID-19 Vaccine Now Authorized
and Recommended for Use in the U.S.
| · | This Emergency Use
Authorization and CDC recommendation makes Novavax’s vaccine the only protein-based non-mRNA COVID vaccine option in the U.S. |
| · | Novavax
expects doses will be available in thousands of locations across the U.S. in the coming days, including CVS Pharmacy and Rite Aid |
| · | Find
Novavax’s vaccine at us.novavaxcovidvaccine.com or vaccines.gov |
GAITHERSBURG, Md., October 3, 2023 –
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its novel Matrix-M™ adjuvant,
today announced that the Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) has received Emergency Use Authorization
(EUA) from the U.S. Food and Drug Administration (FDA) for active immunization to prevent COVID-19 in individuals aged 12 and older.
Immediately upon authorization, Novavax’s vaccine has also been included in the recommendations issued by the U.S. Centers for
Disease Control and Prevention (CDC) on September 12, 2023.
Doses will be available nationwide at thousands
of locations, including national and local retail pharmacies and physicians’ offices, following the Center for Biologics Evaluation
and Research release of vaccine batches, expected in the coming days.
“COVID-19
is once again on the rise with infections and hospitalizations increasing, so it’s important that individuals get vaccinated to
protect themselves and their loved ones,” said John C. Jacobs, President and Chief Executive Officer, Novavax. “Novavax’s
authorization today means people will now have the choice of a protein-based non-MRNA option to help protect themselves against COVID-19,
which is now the fourth leading cause of death in the U.S. In the coming days, individuals in the U.S. can go to pharmacies, physicians’
offices, clinics and various government entities to receive an updated Novavax vaccine.”
The EUA was based
on non-clinical data showing that Novavax’s COVID-19 vaccine induced functional
immune responses against XBB.1.5, XBB.1.16 and XBB.2.3 variants. Additional non-clinical data demonstrated
that Novavax’s vaccine induced neutralizing antibody responses to newly emerging subvariants BA.2.86, EG.5.1 FL.1.5.1 and
XBB.1.16.6 as well as robust CD4+ polyfunctional cellular (T-cell) responses against EG.5.1 and XBB.1.16.6. These data indicate Novavax’s
vaccine can stimulate both arms of the immune system and may induce a broad response against currently circulating variants.1,2
In clinical trials, the most common adverse reactions associated with
Novavax’s prototype COVID-19 vaccine (NVX-CoV2373) included headache, nausea or vomiting, muscle pain, joint pain, injection site
tenderness, injection site pain, fatigue and malaise.
The EUA aligns with globally
harmonized guidance from the FDA, European Medicines Agency and the World Health Organization to target the XBB strain this fall.3-5
Novavax is working with these and other global regulatory authorities on authorizations for its vaccine.
AUTHORIZED USE IN THE U.S.
Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) has not been
approved or licensed by FDA, but has been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19)
for use in individuals 12 years of age and older. Refer to the full Fact Sheet for information about the Novavax COVID-19 Vaccine, Adjuvanted.
The emergency use of this product is only authorized for the duration
of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1)
of the FD&C Act unless the declaration is terminated or authorization revoked sooner.
IMPORTANT SAFETY INFORMATION
What should you mention to your vaccination provider before you
or your child get the Novavax COVID-19 Vaccine, Adjuvanted?
Tell your vaccination provider about all of your or your child’s
medical conditions, including if you or your child:
| · | have had myocarditis (inflammation of the heart muscle) or pericarditis (inflammation
of the lining outside the heart) |
| · | have a bleeding disorder or are on a blood thinner |
| · | are immunocompromised or are on a medicine that affects your immune system |
| · | are pregnant or plan to become pregnant |
| · | have received another COVID-19 vaccine |
| · | have ever fainted in association with an injection |
Who should not get the Novavax COVID-19 Vaccine, Adjuvanted?
A person should not get the Novavax COVID-19 Vaccine, Adjuvanted if
they had:
| · | a severe allergic reaction after a previous dose of any Novavax COVID-19
Vaccine, Adjuvanted |
| · | a severe allergic reaction to any ingredient of these vaccines |
What are the risks of the Novavax COVID-19 Vaccine, Adjuvanted?
There is a remote chance that the vaccine could cause a severe allergic
reaction. A severe allergic reaction would usually occur within a few minutes to one hour after getting a dose. For this reason, the vaccination
provider may ask you or your child to stay at the place where you or your child received the vaccine for monitoring after vaccination.
Signs of a severe allergic reaction can include:
| · | Swelling of the face and throat |
| · | A bad rash all over your body |
Myocarditis (inflammation of the heart muscle) and pericarditis (inflammation
of the lining outside the heart) have occurred in some people who have received the vaccine. In most of these people, symptoms began within
10 days following vaccination. The chance of having this occur is very low. You should seek medical attention right away if you or your
child have any of the following symptoms after receiving the vaccine:
| · | Feelings of having a fast-beating, fluttering, or pounding heart |
Side effects that have been reported in clinical trials with the Novavax
COVID-19 Vaccine, Adjuvanted include:
| · | Myocarditis (inflammation of the heart muscle) |
| · | Pericarditis (inflammation of the lining outside the heart) |
| · | Injection site reactions: pain/tenderness, swelling, redness and itching |
| · | General side effects: fatigue or generally feeling unwell, muscle pain, headache,
joint pain, nausea, vomiting, fever, chills |
| · | Allergic reactions such as hives and swelling of the face |
Side effects that have been reported in post-authorization use with
the Novavax COVID-19 Vaccine, Adjuvanted include:
| · | Severe allergic reactions |
| · | Myocarditis (inflammation of the heart muscle) |
| · | Pericarditis (inflammation of the lining outside the heart) |
| · | Paresthesia (unusual feeling in the skin such as tingling or a crawling feeling) |
| · | Hypoesthesia (decreased feeling or sensitivity, especially in the skin) |
These may not be all the possible side effects. Serious and unexpected
side effects may occur. The possible side effects are still being studied.
What should I do about side effects?
If you or your child experience a severe allergic reaction, call 9-1-1,
or go to the nearest hospital.
Call the vaccination provider or your healthcare provider for any side
effects that bother you or your child or do not go away.
Report vaccine side effects to the FDA and the Centers for Disease
Control and Prevention (CDC) Vaccine Adverse Event Reporting System (VAERS). The VAERS toll-free number is 1-800-822-7967 or report online
to https://vaers.hhs.gov/reportevent.html. Please include “Novavax COVID-19 Vaccine,
Adjuvanted (2023-2024 Formula) EUA” in the first line of box #18 of the report form.
In addition, you can report side effects to Novavax, Inc., using the
following contact information: Website: www.NovavaxMedInfo.com, Fax Number: 1-888-988-8809,
Telephone Number: 1-844-NOVAVAX (1-844-668-2829).
What about pregnancy or breastfeeding?
If you or your child are pregnant or breastfeeding, discuss the options
with your healthcare provider.
There is a pregnancy exposure registry that monitors pregnancy outcomes
in women exposed to the Novavax COVID-19 Vaccine, Adjuvanted during pregnancy. Women who are vaccinated with the Novavax COVID-19 Vaccine,
Adjuvanted during pregnancy are encouraged to enroll in the registry by visiting https://c-viper.pregistry.com.
Please see the Fact
Sheet for Recipients and Caregivers for more information. Reporting Adverse Events and Vaccine Administration Errors
| · | Adverse
events can also be reported to Novavax, Inc. using the following contact information or by
providing a copy of the VAERS form to Novavax, Inc. Website: https://www.novavaxmedinfo.com/,
Fax Number: 1-888-988-8809, Telephone Number: 1-844-NOVAVAX (1-844-668-2829). |
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved
health by discovering, developing and commercializing innovative vaccines to protect against serious infectious diseases. Novavax, a
global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach,
innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world’s
most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined.
Please visit novavax.com and LinkedIn for more
information.
Forward-Looking Statements
Statements herein relating to the future of Novavax,
its operating plans and prospects, the scope, timing and outcome of future regulatory filings and actions, including the availability
of its updated XBB version of its Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) and the timing of delivery and
distribution of its vaccine are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous
risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These
risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy,
and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy
applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital
and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges or delays in obtaining regulatory
authorization for its product candidates, including its updated XBB version of its COVID-19 vaccine in time for the fall 2023 vaccination
season or for future COVID-19 variant strain changes; challenges or delays in clinical trials; manufacturing, distribution or export
delays or challenges; Novavax’s exclusive dependence on Serum Institute of India Pvt. Ltd. for co-formulation and filling and the
impact of any delays or disruptions in their operations on the delivery of customer orders; challenges in obtaining commercial adoption
of our updated protein-based non-mRNA XBB COVID-19 vaccine, NVX-CoV2373 or any COVID-19 variant strain-containing formulation; challenges
meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors
identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations"
sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent Quarterly Reports on Form 10-Q,
as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking
statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov
and www.novavax.com, for a discussion of these and other risks and uncertainties.
The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update
or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors,
potential investors, and others should give careful consideration to these risks and uncertainties.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Ali Chartan
240-720-7804
media@novavax.com
References
| 1. | Wherry EJ, Barouch DH. T cell immunity to COVID-19 vaccines. Science. 2022;377(6608):821-822. doi:10.1126/science.add2897. |
| 2. | Markov PV, Ghafari M, Beer M, et al. The evolution of SARS-CoV-2.
Nat Rev Microbiol. 2023;21(6):361-379. doi:10.1038/s41579-023-00878-2. |
| 3. | U.S. Food and Drug
Administration (FDA). Updated COVID-19 vaccines for use in the United States beginning in
fall 2023. June 16, 2023. https://www.fda.gov/vaccines-blood-biologics/updated-covid-19-vaccines-use-united-states-beginning-fall-2023. |
| 4. | European Medicines
Agency (EMA). EMA and ECDC statement on updating COVID-19 vaccines to target new SARS-CoV-2
virus variants. June 6, 2023. https://www.ema.europa.eu/en/news/ema-ecdc-statement-updating-covid-19-vaccines-target-new-sars-cov-2-virus-variants. |
| 5. | World Health Organization (WHO). XBB.1.5
updated risk assessment. June 20, 2023. https://www.who.int/docs/default-source/coronaviruse/20230620xbb.1.5.pdf?sfvrsn=fff6f686_3. |
v3.23.3
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024
